Target intelligence / Profile preview

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta (PI3K delta) (PI3K delta)

Target
PI3K delta
Molecular classification
Enzyme, Kinase, Lipid kinase, Phosphoinositide 3-kinase family, Class IA PI3K
01

Overview

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta (PI3K delta) is a member of the Class IA phosphoinositide 3-kinase family, primarily expressed in hematopoietic cells such as B cells, T cells, and myeloid cells [1.2.1, 1.4.1]. It functions as a lipid kinase that phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the plasma membrane, a critical second messenger that recruits PH-domain-containing proteins like AKT and PDK1 [1.3.2, 1.4.2]. This signaling cascade is vital for the development, activation, and survival of lymphocytes and other immune cells [1.2.2, 1.4.2]. Overactivation of PI3K delta, often through gain-of-function mutations in the PIK3CD gene, leads to Activated PI3K Delta Syndrome (APDS), while its dysregulation is a hallmark of various B-cell malignancies [1.2.3, 1.4.3]. Selective inhibitors of PI3K delta have been developed to treat chronic lymphocytic leukemia, follicular lymphoma, and APDS by blocking the aberrant survival signals in these cells [1.1.5, 1.4.3]. However, therapeutic use is often limited by immune-mediated toxicities, including colitis and pneumonitis, which result from the disruption of immune homeostasis [1.1.1, 1.1.2].

Other names
PIK3CDp110 deltap110δPhosphoinositide 3-kinase deltaPtdIns-3-kinase subunit deltaIMD14APDS
02

Mechanism of action

Selective inhibition of the p110δ catalytic subunit of Class IA PI3K, preventing the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) and subsequent activation of the AKT/mTOR signaling pathway in leukocytes [1.3.2, 1.4.1, 1.4.2].

03

Biological functions

Signal transductionImmune responseCell proliferationCell differentiationB cell activationT cell activationCytokine production
04

Disease associations

CancerHematologic malignancyAutoimmunityInflammationPrimary immunodeficiencyActivated PI3K delta syndrome (APDS)
05

Safety considerations

Autoimmune colitisHepatotoxicity (transaminitis)PneumonitisOpportunistic infections (Pneumocystis jirovecii pneumonia, Cytomegalovirus)Neutropenia
06

Interacting drugs

Idelalisib

6 more in the full profile.

07

Biomarkers

PIK3CD mutationPhospho-AKT levelsCD19+ B-cell countSerum cytokine levels

Beyond the preview

Go deeper on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta (PI3K delta) (PI3K delta).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta (PI3K delta) (PI3K delta).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call